The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.

Schreiber, Anna R; O'Bryant, Cindy L; Kabos, Peter; Diamond, Jennifer R

Schreiber, Anna R; O'Bryant, Cindy L; Kabos, Peter; Diamond, Jennifer R.

Afiliação

Schreiber AR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
O'Bryant CL; Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kabos P; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Diamond JR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Expert Rev Anticancer Ther ; 23(10): 1061-1069, 2023.

Article em En | MEDLINE | ID: mdl-37742278

Assuntos

Neoplasias da Mama; Imunoconjugados; Neoplasias de Mama Triplo Negativas; Humanos; Feminino; Neoplasias da Mama/tratamento farmacológico; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Trastuzumab; Imunoconjugados/efeitos adversos; Camptotecina/farmacologia; Receptor ErbB-2

Palavras-chave

Antibody-drug conjugate (ADC); fam-trastuzumab deruxtecan (T-DXd); human epidermal growth factor receptor 2 (HER2)-low; topoisomerase I; triple-negative breast cancer (TNBC)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Imunoconjugados / Neoplasias de Mama Triplo Negativas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google